Abstract
Background: Insulin Autoimmune Syndrome (IAS) is a rare condition characterized by the combination of recurrent severely spontaneous hypoglycemia without evidence of exogenous insulin administration, high concentration of total serum insulin, and the presence of a high titer of insulin autoantibody (IAA). But now we describe a case with IAS caused by gliclazide and hardly occuring hypoglycemia.
Case Report: A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high. He had no exogenous insulin administration history. Switching antidiabetic therapy from gliclazide to acarbose and metformin, the patient’s serum insulin level and IAA decreased gradually. Accordingly, the glycemic control improved and there was no episode of hypoglycemia. Conclusion: Hence, clinicians should pay more attention to type 2 diabetic patients treated with gliclazide and detect their serum insulin concentration and IAA to exclude or diagnose IAS and perform the best therapeutic regimen to these patients.Keywords: Gliclazide, hypoglycemia, insulin autoantibodies, insulin autoimmune syndrome, insulin resistance.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature
Volume: 16 Issue: 4
Author(s): Xiu Feng, Lu Yuan, Yun Hu, Yunqing Zhu, Fan Yang, Lanlan Jiang, Rengna Yan, Yong Luo, Enhui Zhao, Chenxiao Liu, Ying Wang, Qi Li, Xin Cao, Qian Li and Jianhua Ma
Affiliation:
Keywords: Gliclazide, hypoglycemia, insulin autoantibodies, insulin autoimmune syndrome, insulin resistance.
Abstract: Background: Insulin Autoimmune Syndrome (IAS) is a rare condition characterized by the combination of recurrent severely spontaneous hypoglycemia without evidence of exogenous insulin administration, high concentration of total serum insulin, and the presence of a high titer of insulin autoantibody (IAA). But now we describe a case with IAS caused by gliclazide and hardly occuring hypoglycemia.
Case Report: A 70-year-old man with type 2 diabetes presented to our department with poor glycemic control without evidence of hypoglycemia, but the levels of serum insulin and IAA were very high. He had no exogenous insulin administration history. Switching antidiabetic therapy from gliclazide to acarbose and metformin, the patient’s serum insulin level and IAA decreased gradually. Accordingly, the glycemic control improved and there was no episode of hypoglycemia. Conclusion: Hence, clinicians should pay more attention to type 2 diabetic patients treated with gliclazide and detect their serum insulin concentration and IAA to exclude or diagnose IAS and perform the best therapeutic regimen to these patients.Export Options
About this article
Cite this article as:
Feng Xiu, Yuan Lu, Hu Yun, Zhu Yunqing, Yang Fan, Jiang Lanlan, Yan Rengna, Luo Yong, Zhao Enhui, Liu Chenxiao, Wang Ying, Li Qi, Cao Xin, Li Qian and Ma Jianhua, Gliclazide-Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (4) . https://dx.doi.org/10.2174/1871530316666161223144558
DOI https://dx.doi.org/10.2174/1871530316666161223144558 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Anti-Angiogenic Agents (Executive Editor: Maurizio Botta and Anna Di Donna)]
Current Pharmaceutical Design Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews A Therapeutic Connection between Dietary Phytochemicals and ATP Synthase
Current Medicinal Chemistry Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Editorial [Hot Topic: Food-Derived Bioactive Proteins and Peptides as Potential Components of Nutraceuticals (Executive Editor: H. Meisel)]
Current Pharmaceutical Design Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam
Central Nervous System Agents in Medicinal Chemistry Bier Spots - Report of Two Cases and Review of the Literature
Current Rheumatology Reviews Improved Sensory Blockade by Clonidine Added to Axillary Block Solution. Resulting Plasma Clonidine Concentration
Letters in Drug Design & Discovery Antioxidant Profile of Home Prepared <i>Taraxacum Officinale</i> Weber Ex Wigg Beverage
Current Nutraceuticals A Dual Activity of ROS and Oxidative Stress on Adult Neurogenesis and Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Ruta Montana Evokes Antihypertensive Activity Through an Increase of Prostaglandins Release in L-NAME-Induced Hypertensive Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Main Isoflavones Found in Dietary Sources as Natural Anti-inflammatory Agents
Current Drug Targets Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Peculiaritie of Distribution of Polymorphic Variants of IL1Β Gene in Patients with Atherosclerosis and Metabolic Syndrome
Current Pharmacogenomics and Personalized Medicine